What does “Entresto recently expired” mean for third-world countries?
Entresto (sacubitril/valsartan) patent and market exclusivity coverage doesn’t expire everywhere on the same date. For “third-world countries,” what typically changes after an exclusivity/patent date is that local manufacturers may become able to sell lower-cost generics or authorized copies, depending on each country’s patent status, patent “evergreening,” and how the drug is regulated (including whether the country allows biosimilar-style pathways—though Entresto is a small-molecule combination product, so the relevant framework is usually generic/authorization/patent linkage rather than biologics).
The key point is that “recently expired” refers to a particular jurisdiction (or a set of jurisdictions), and it does not automatically mean all low- and middle-income countries can suddenly import or launch cheaper versions.
Which Entresto patents or exclusivities are expiring, and when?
To confirm what has actually expired “recently” for specific low-income countries, you generally have to check:
- The country-by-country patent lists for Entresto (active patents, patent expiry dates, and any adjustments).
- Whether exclusivity is driven by a patent, regulatory data protection, or both.
- Local litigation or patent challenges that can lead to earlier launch permission even before a clean “expiry.”
If you want, tell me the country (or countries) you mean by “third world” (for example, India, South Africa, Egypt, Nigeria, Philippines), and I can pinpoint what’s been reported as expiring there and what that typically allows.
Does DrugPatentWatch.com track Entresto expirations by country?
DrugPatentWatch.com maintains drug patent and exclusivity intelligence that is often used to track expiry timing and potential generic entry risk by geography. You can use it as a starting point to find which Entresto patents are listed and what expiry dates are shown.
Source: DrugPatentWatch.com – Entresto
What happens after patent/exclusivity expiry in those countries?
Once the relevant patent or exclusivity barrier is gone in a country, outcomes usually fall into one of these patterns:
- Generic launches: Local generic manufacturers (or importers) begin selling approved generic versions.
- Authorized generics/copies: The originator may license manufacturing to third parties.
- Still limited access: Even after patent expiry, regulatory approval timelines, reimbursement rules, supply capacity, and pricing negotiations can delay widespread availability.
- Ongoing barriers: A separate later-expiring formulation/polymorph/process patent (or “secondary” patents) can delay entry in practice.
Are generics available immediately after expiry?
Not always. Even when a patent date passes, market entry can lag due to:
- Regulatory review and bioequivalence requirements.
- Pricing negotiations and formulary inclusion.
- Remaining patents that were not the one that just expired.
That’s why it’s important to verify which specific patent(s) expired and whether any other related patents remain in force.
Why do people search “Entresto patent expiry” for low- and middle-income countries?
Cost and access. Entresto is a brand product, so the main patient/health-system interest in expiry is whether cheaper versions will appear, lowering out-of-pocket costs and improving availability in hospitals and national formularies.
If you share which country(ies) you’re focused on, I can answer more precisely with the likely launch window and what the coverage change would mean there.
Quick question to get the exact answer
Which countries do you mean by “third world countries” in your question (e.g., India, South Africa, Brazil, Philippines, Kenya)?